bell potter research, page-11

what? really??

PI-88 does NOT "just manage symptoms". It inhibits tumour growth and metastisis. There is no approved drug therapy for post-resection liver cancer; and no other drug for the disease in late stage development. More to the point, blockbusters like Avastin extend survivial by a couple of months yet manage to generate annual sale sof over USD$2 billion!! AND it is very unlikey that a total CURE for cancer will be found anytime soon.

Assuming all goes well, PI-88 should have a long "shelf life" after approval.

PI-88 is a HUGE opportunity for Progen.